Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

Search Term: Irinotecan

NCT Trial Name# of Centers


  Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors


  Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors


  Metformin in Children With Relapsed or Refractory Solid Tumors


  Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers


  Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma


  External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas


  Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer


  Pilot Study to Determine Biodistribution of MM-398 and Feasibility of Ferumoxytol as a Tumor Imaging Agent


  Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors


  Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors


  Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery


  A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas


  Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma


  A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma


  Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma


  Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer


  Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma


  Bevacizumab Beyond Progression (BBP)


  Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma


  A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases


  Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors


  Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With Glioblastoma Multiforme Measured Compared to Avastin/Irinotecan


  Irinotecan Combination Chemotherapy for Refractory or Relapsed Brain Tumor in Children and Adolescents


  Irinotecan in Combination With Cisplatin in Pediatric Patients With Unfavorable Prognosis Gliomas


  Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma


  Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors


  Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA


  Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)


  Radiosurgery Plus Bevacizumab in Glioblastoma


  Aloxi for Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Malignant Glioma (MG) Patients Receiving Irinotecan With Bevacizumab


  A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas


  A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas


  Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma


  CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With DIPG


  Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients


  Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer


  BrUOG 329 GBM Onyvide With TMZ


  Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas


  Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma


  Safety Study of Afatinib for Brain Cancer


  A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas


  Phase II Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer


  Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme


  Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Surgically Resectable Glioblastoma Multiforme.

Brain Tumor News Articles About Irinotecan

  1. [03/10/2019] Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study.  This looks good for recurrent GBM.  It is too small of a study to tell for sure but the survivals compare very well to historical survivals.  We need to follow all patients who use Optune to see which combinations are the best, and this opens the door for more research on using Optune for recurrent GBM.

  2. [12/03/2017] Correction regarding dose of Avastin in an old article  This correction just came out. In this article about Avastin for GBMs from 2008, they used the wrong units for the dosage calculation. The correct units are mg per kilogram, not the mg per square meter of body surface area that they originally reported.  The difference is huge. For a typical 200 pound 6' tall patient, at 5mg per square meter, the incorrect dose would be about 10mg of Avastin.  Using the correct formula, 5mg per kg,  it would be about 450 mg.   Note that the correct dose of Avastin is not really known. Some use 5mg per kg, some 10mg per kg and some higher doses.

  3. [03/17/2016] Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. Impressive gain in progression free survival. These trials should NOT even try to report on overall survival. They say 83% of patients in the control group took Avastin at the time of recurrence.  So they are comparing patients who took Avastin to patients who took Avastin and found no difference in overall survival. Duh.  

  4. [08/04/2014] MD Andesron Reviewed Study Reveals Bevacizumab/lomustine Combination Improved Recurrent Glioblastoma Outcomes  This study shows relatively good results for the combination of Avastin and lomustine. It also showed disappointing results for Avastin alone. However, the bottom line was almost all patients died, so we need more work to get better treatments.

  5. [07/04/2014] Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis Good results.  I like the idea of adding the checkpoint inhibitor to increase the effect of the vaccine.

  6. [04/13/2014] Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared to temozolomide-chemoradiation for unresectable glioblastoma. Final results of the TEMAVIR study from ANOCEF.  This trial did not show much benefit for using Avastin and Irinotecan for newly diagnosed unresectable GBMs.  There was no difference in overall survival, however, the patients in the control group were able to cross over when the progressed, and there was about a 2 month advantage in time to progression.

  7. [12/18/2013] Positive Phase 2 Results from Agenus` Brain Cancer Vaccine Published in Neuro-Oncology  Pretty good news on a vaccine trial....  there was no control group but it beat historical controls. Survival (I assume after recurrence) was 11 months for the vaccine, compared to 3 to 9 months for historical controls.  

  8. [06/01/2013] Genentech Announces Final Phase III Study Results of Avastin Plus Radiotherapy and Chemotherapy in People with an Aggressive Form of Brain Cancer This trial looked at a large number of newly diagnosed GBM patients.  1/2 received the standard treatment of Surgery, Radiation and Temodar during radiation and for 6 months afterwards, or that same treatment + Avastin until recurrence.  Temodar was stopped after 6 cycles in both groups.  The results weren't as good as we were hoping for but they are a small step foward. They reported no difference in median overall survival, but there was a big increase in progression free survival in the Avastin group ( 8.4 months vs. 4.3 months), as well as the % of patients alive at the 1 and 2 year points.  "Seventy-two percent of people treated in the Avastin arm were alive at one year compared to 66 percent of people in the placebo arm (p=0.049). Thirty-four percent were alive at two years compared to 30 percent, respectively (p=0.235)."   In human terms this means that although on average both groups lived about the same length of time, the Avastin group was in better shape for most of that time.  This is very important. And more of the patients in the Avastin group went on to do much better than the ones in standard of care group.    So it looks like Avastin should play a role in the treatment of GBM but the question now become what is the best way to use it? For newly diagnosed or at recurrence? (It is already approved for recurrent GBM). Or perhaps in combination with other treatments. More research is needed.  We (The Musella Foundation) has been funding exciting research looking at ways to make Avastin work better. Hopefully we can figure out why it helps some patients and not others, then make it work for all.   (Disclosure: Genetech - the makers of Avastin - is one of our sponsors)  

  9. [05/18/2013] Irinotecan delivery by microbubble-assisted ultrasound: in-vitro validation and a pilot preclinical study.  Irinotecan (CPT-11) looked like a very promising drug in the test tube and with other cancers, so it was tried IV in clinical trials with Avastin.  It did slightly better but probably not worth the extra side effects.  This project looks at a different way to get the drug into the brain at a higher concentration  without hurting the rest of the body. I love concepts like this. IF they can get a high concentration in the brain, it may work much better.

  10. [11/30/2012] Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen.  This talks about the combination of Avastin and CPT-11 for recurrent glioblastoma.  They compared patients who took this combination with patients who did all other available treatments and this group did better by 7 months (70%).   Previous similiar studies showed a similiar benefit but when avastin alone was tested with avastin + CPT-11, the results were pretty close - the avastin + CPT-11 group did a little better but had more side effects. Not clear which is best yet.  

  11. [11/19/2012] Genentech Study Showed That Avastin Helped People with Newly Diagnosed Glioblastoma Live Longer with  This was the big news at the Society of Neuro-oncology conference this weekend.  There was about a 50% improvement in progression free survival by adding Avastin to the standard treatment, over using the standard treatment alone.  This means that patients feel better and can take care of themeselves longer with Avastin than without.    However, the question remains when is the best time to use Avastin, right at the start or wait for recurrence. That question is not yet answered.   There seems to be (but hasn't been tested yet) about the same time benefit for using at it the time of recurrence rather than at the start.  (Although using it at the start allowed patients to functional at the highest level for a longer period of time. )  My own thoughts (and I am not an MD - so take it for what it is worth):  My preference would be to enter a clinical trial for newly diagnosed GBM patients and hold off on the Avastin until the time of recurrence. IF you can not enter a trial, then it is a toss-up on when the best time to start Avastin would be. Either way can be argued.  There are more trials (such as the Tocagen trial) that now allow you to enter after having had Avastin, so that removes one of the barriers to using Avastin upfront.   Disclosure: Genetech is a sponsor of the Musella Foundation

  12. [05/03/2012] A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.

  13. [10/22/2011] Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

  14. [07/28/2011] Bevacizumab (Avastin)and daily temozolomide (Temodar)for recurrent glioblastoma.

  15. [07/12/2011] Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.

  16. [06/16/2011] Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

  17. [05/10/2011] Merrimack Pharmaceuticals Acquires European and Asian Rights to MM-398, nanoliposomal irinotecan

  18. [05/07/2011] The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide and Irinotecan for Newly Diagnosed Glioblastoma.

  19. [03/28/2011] APP Pharmaceuticals Issues A Nationwide Voluntary Recall Of Irinotecan Hydrochloride Injection (CPT-11)

  20. [03/12/2011] Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

  21. [02/08/2011] Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.

  22. [02/01/2011] Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence.

  23. [01/24/2011] Conversion of brain tumor cells into blood vessels thwarts treatment efforts

  24. [12/01/2010] Bevacizumab Combinations Effective in Phase II Glioblastoma Trials

  25. [06/08/2010] BRAIN: 16% of patients with relapsed glioblastoma alive at 30 months (Avastin)

  26. [05/22/2010] Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study.

  27. [04/23/2010] Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

  28. [04/15/2010] IBTA April 2010 E-News

  29. [01/28/2010] New therapies improving survival in patients with glioblastoma

  30. [12/06/2009] IBTA Newsletter

  31. [11/21/2009] Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

  32. [11/21/2009] European advisory committee declines to recommend Avastin approval for deadly brain cancer

  33. [09/24/2009] Bevacizumab (Avastin) Could Play An Important Role In Improving The Neurocognitive Function Of Patients With The Most Aggressive Form Of Brain Cancer

  34. [09/07/2009] Small Cap Stocks Battling Brain Cancer

  35. [06/20/2009] Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab (Avastin)

  36. [05/14/2009]


  38. [04/01/2009] FDA Advisory Committee Unanimously Recommends Accelerated Approval of Avastin for Previously Treated Brain Cancer (Glioblastoma)

  39. [03/04/2009] Bevacizumab (Avastin) for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

  40. [01/07/2009] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma.

  41. [12/31/2008] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma.

  42. [12/31/2008] Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.

  43. [11/19/2008] Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab (Avastin) plus irinotecan (CPT-11).

  44. [10/17/2008] Experience with irinotecan for the treatment of malignant glioma

  45. [10/04/2008] Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM).

  46. [10/04/2008] Phase II study of bevacizumab and etoposide in patients with recurrent malignant glioma.

  47. [10/04/2008] Update on survival from the original phase II trial of bevacizumab and irinotecan in recurrent malignant gliomas.

  48. [10/04/2008] A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).

  49. [10/04/2008] Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen.

  50. [10/04/2008] A phase II trial with cetuximab, bevacizumab, and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolamide.

  51. [10/03/2008] Comparative analysis of temozolomide (TMZ) versus 1,3-bis (2-chloroethyl)-1 nitrosourea (BCNU) in newly diagnosed glioblastoma multiforme (GBM) patients.

  52. [09/13/2008] Experience with irinotecan (CPT-11) for the treatment of malignant glioma

  53. [08/10/2008] Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases.

  54. [07/29/2008] A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

  55. [07/16/2008] Glioblastoma multiforme.

  56. [06/09/2008] Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors.

  57. [05/16/2008] Avastin improves brain cancer survival

  58. [03/18/2008] Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

  59. [02/27/2008] Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme

  60. [12/19/2007] Brain Cancer Drug Looks Very Promising

  61. [11/19/2007] Genentech Reveals Encouraging Avastin Data; Bayer`s Nexavar Gets FDA Approval For Liver Cancer - Update [DNA]

  62. [11/16/2007] Bevacizumab (Avastin) plus irinotecan (CPT-11) in recurrent glioblastoma multiforme.

  63. [10/31/2007] Bevacizumab (Avastin) plus irinotecan (CPT-11) in recurrent glioblastoma multiforme.

  64. [10/22/2007] Drug may stave off brain tumor deaths

  65. [10/19/2007] Avastin seen as helpful against deadly brain tumor

  66. [09/20/2007] Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts

  67. [06/16/2007] Predicting treatment responses earlier for brain tumor patients

  68. [04/18/2007] Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.

  69. [04/09/2007] Phase II trial of bevacizumab (Avastin) and irinotecan (CPT-11) in recurrent malignant glioma.

  70. [04/09/2007] Phase II trial of bevacizumab (Avastin) and irinotecan (CPT-11) in recurrent malignant glioma.

  71. [03/04/2007] Avastin halts brain cancer

  72. [03/03/2007] U.S. study finds drug Avastin helps brain tumors

  73. [01/26/2007] Advances in the Management of Glioblastoma Multiforme: An Expert Interview With Dr. Renato La Rocca From 2006 SNO

  74. [01/07/2007] Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin

  75. [05/02/2006] Salvage chemotherapy With CPT-11 for recurrent meningioma.

  76. [10/28/2005] Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.

  77. [10/05/2005] Irinotecan (CPT-11) Therapy in a 12-year-old Girl with Recurrent Brain Stem Glioma and without Functional Polymorphisms in UGT1A1 Activity: Case Report.

  78. [08/20/2005] Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.

  79. [08/09/2005] Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.


  81. [12/06/2004] Second-Line Chemotherapy With Irinotecan Plus Carmustine in Glioblastoma Recurrent or Progressive After First-Line Temozolomide Chemotherapy: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

  82. [12/01/2004] Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children.

  83. [06/08/2004] High-dose (HD) irinotecan in patients with recurrent unresectable high-grade gliomas on glucoronidation-enhancing anticonvulsants (GEACs): A phase I/II study.

  84. [05/26/2004] A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma.

  85. [02/12/2004] FDA Approves Erbitux for Colorectal Cancer

  86. [06/14/2003] Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: A North American Brain Tumor Consortium (NABTC) study

  87. [05/14/2003] Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer

  88. [04/29/2003] Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.

  89. [04/29/2003] Effect of intrapatient dosage escalation of irinotecan on its pharmacokinetics in pediatric patients who have high-grade gliomas and receive enzyme-inducing anticonvulsant therapy.

  90. [04/29/2003] Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.

  91. [04/29/2003] The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors.

  92. [04/29/2003] Irinotecan in the treatment of glioma patients.

  93. [08/25/2002] Herbal Dietary Supplement Alters Metabolism Of Chemotherapy Drug Editor`s Note: irinotecan is also known as CPT-11, and is being used for brain tumor treatments.

  94. [02/08/2001] The Present and Future of Cancer Therapy: `The Oncologist Journal` Reports on Versatile New Anti-Cancer Drug Irinotecan (PR Newswire)
    ..., has been shown to increase progression-free survival, delay tumor growth and also is showing potential in other cancer types......., esophageal cancer, gastric cancer, cervical cancer, malignant brain tumors and ovarian cancer,`` as well as pancreatic cancer....
    - Feb 08 4:10 PM ET

  95. [04/20/2000] FDA Grants Marketing Approval to CAMPTOSAR(R) for First-Line Treatment of Metastatic Colorectal Cancer (PR Newswire)
    Pharmacia Corporation announced today that the U.S. Food and Drug Administration approved CAMPTOSAR(R), as first-line therapy for the treatment of patients with metastatic colorectal cancer in combination with 5-fluorouracil/leucovorin.
    - Apr 20 5:10 PM ET

  96. [03/27/2000] Combination Regimen Containing CAMPTOSAR(R) Increases Survival for Metastatic Colorectal Cancer Patients According To Lancet Study (PR Newswire)
    A study published in the March 25, 2000 issue of Lancet demonstrated that CAMPTOSAR(R) in combination with first-line therapy significantly improved survival and tumor response compared with 5-FU/LV alone in metastatic colorectal cancer patients.
    - Mar 27 8:04 AM ET

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557